<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ANG</journal-id>
<journal-id journal-id-type="hwp">spang</journal-id>
<journal-id journal-id-type="nlm-ta">Angiology</journal-id>
<journal-title>Angiology</journal-title>
<issn pub-type="ppub">0003-3197</issn>
<issn pub-type="epub">1940-1574</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0003319711409200</article-id>
<article-id pub-id-type="publisher-id">10.1177_0003319711409200</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Coronary Heart Disease</subject>
</subj-group>
</article-categories>
<title-group><article-title>Prevalence, Predictors, and Outcomes of Conservative Medical Management in Non-ST-Segment Elevation Acute Coronary Syndromes in Gulf RACE-2</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>AlHabib</surname>
<given-names>Khalid F.</given-names>
</name>
<degrees>FRCPC</degrees>
<xref ref-type="aff" rid="aff1-0003319711409200">1</xref>
<xref ref-type="corresp" rid="corresp1-0003319711409200"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hersi</surname>
<given-names>Ahmad</given-names>
</name>
<degrees>FRCPC</degrees>
<xref ref-type="aff" rid="aff1-0003319711409200">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alsheikh-Ali</surname>
<given-names>Alawi A.</given-names>
</name>
<degrees>FACC</degrees>
<xref ref-type="aff" rid="aff2-0003319711409200">2</xref><xref ref-type="aff" rid="aff3-0003319711409200">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sulaiman</surname>
<given-names>Kadhim</given-names>
</name>
<degrees>FRCP</degrees>
<xref ref-type="aff" rid="aff4-0003319711409200">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alfaleh</surname>
<given-names>Hussam</given-names>
</name>
<degrees>FRCPC</degrees>
<xref ref-type="aff" rid="aff1-0003319711409200">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alsaif</surname>
<given-names>Shukri</given-names>
</name>
<degrees>FRCP</degrees>
<xref ref-type="aff" rid="aff5-0003319711409200">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Almahmeed</surname>
<given-names>Wael</given-names>
</name>
<degrees>FRCPC</degrees>
<xref ref-type="aff" rid="aff6-0003319711409200">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Asaad</surname>
<given-names>Nidal</given-names>
</name>
<degrees>FRCPC</degrees>
<xref ref-type="aff" rid="aff7-0003319711409200">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Amin</surname>
<given-names>Haitham</given-names>
</name>
<degrees>FRCPC</degrees>
<xref ref-type="aff" rid="aff8-0003319711409200">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Al-Motarreb</surname>
<given-names>Ahmed</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff9-0003319711409200">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Al-Lawati</surname>
<given-names>Jawad</given-names>
</name>
<degrees>MPH</degrees>
<xref ref-type="aff" rid="aff10-0003319711409200">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Suwaidi</surname>
<given-names>Jassim Al</given-names>
</name>
<degrees>FACC</degrees>
<xref ref-type="aff" rid="aff7-0003319711409200">7</xref>
</contrib>
</contrib-group>
<aff id="aff1-0003319711409200"><label>1</label>King Fahad Cardiac Center, College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia</aff>
<aff id="aff2-0003319711409200"><label>2</label>Division of Cardiology, Institute of Cardiac Sciences, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates</aff>
<aff id="aff3-0003319711409200"><label>3</label>Tufts Clinical and Translational Science Institute, Tufts Medical Center, Boston, MA, USA</aff>
<aff id="aff4-0003319711409200"><label>4</label>Department of Cardiology, Royal Hospital, Muscat, Oman</aff>
<aff id="aff5-0003319711409200"><label>5</label>Saud AlBabtain Cardiac Center, Dammam, Kingdom of Saudi Arabia</aff>
<aff id="aff6-0003319711409200"><label>6</label>Department of Cardiology, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates</aff>
<aff id="aff7-0003319711409200"><label>7</label>Department of Cardiology, Hamad Medical Corporation (HMC), Doha, Qatar</aff>
<aff id="aff8-0003319711409200"><label>8</label>Mohammed Bin Khalifa Cardiac Center, Manama, Bahrain</aff>
<aff id="aff9-0003319711409200"><label>9</label>Faculty of Medicine, Sana’s University, Sana’a, Yemen</aff>
<aff id="aff10-0003319711409200"><label>10</label>Department of Non-Communicable Diseases Surveillance and Control, Ministry of Health, Muscat, Oman</aff>
<author-notes>
<corresp id="corresp1-0003319711409200">Khalid F. AlHabib, King Fahad Cardiac Center, King Khalid University Hospital, College of Medicine, King Saud University, PO Box 7805, Riyadh 11472, Kingdom of Saudi Arabia Email:<email>khalidalhabib13@hotmail.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2012</year>
</pub-date>
<volume>63</volume>
<issue>2</issue>
<fpage>109</fpage>
<lpage>118</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>We assessed the prevalence, predictors, and in-hospital and long-term outcomes of conservative medical management for patients with non-ST-segment elevation acute coronary syndrome (NSTEACS) compared with percutaneous coronary intervention (PCI) and coronary artery bypass graft surgery (CABG). This prospective study conducted from October 2008 to June 2009 in 65 hospitals from 6 Arabian Gulf countries included 30-day and 1-year mortality follow-up for 3661 patients. Compared with conservative management group (2859 patients; 78.1%), the PCI group (638; 17.4%) had significantly better unadjusted and adjusted in-hospital (odds ratio [OR]: 0.40, 95% confidence interval [CI]: 0.17-0.97), 30-day (OR: 0.44, 95% CI: 0.24-0.76) and 1-year (OR: 0.58, 95% CI: 0.40-0.87) mortality rates. Comparison with the CABG group (164; 4.5%) yielded similar results with inclusion of patients scheduled for CABG after hospital discharge. Independent predictors of conservative medical management were mainly country of residence and history of prior CABG.</p>
</abstract>
<kwd-group>
<kwd>conservative medical management</kwd>
<kwd>coronary artery disease</kwd>
<kwd>non–ST-segment elevation acute coronary syndrome</kwd>
<kwd>Gulf RACE-2</kwd>
<kwd>registry</kwd>
<kwd>Middle East</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0003319711409200">
<title>Introduction</title>
<p>The American College of Cardiology and the European Society of Cardiology have recommended that patients with intermediate- to high-risk non-ST-segment elevation acute coronary syndrome (NSTEACS) will benefit from an early invasive strategy compared with conservative medical management.<sup><xref ref-type="bibr" rid="bibr1-0003319711409200">1</xref>,<xref ref-type="bibr" rid="bibr2-0003319711409200">2</xref></sup> Several randomized controlled trials have demonstrated the benefit of early invasive management in such populations.<sup><xref ref-type="bibr" rid="bibr3-0003319711409200">3</xref><xref ref-type="bibr" rid="bibr4-0003319711409200"/><xref ref-type="bibr" rid="bibr5-0003319711409200"/>–<xref ref-type="bibr" rid="bibr6-0003319711409200">6</xref></sup> However, “invasive” management with a diagnostic coronary angiogram is not equivalent to undergoing revascularization with either percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG). Furthermore, the CRUSADE (Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early implementation of the ACC/AHA Guidelines) quality improvement initiative showed that only one quarter of NSTEACS patients with triple-vessel coronary artery disease (CAD) had revascularization.<sup><xref ref-type="bibr" rid="bibr7-0003319711409200">7</xref></sup> It also showed that the use of cardiac catheterization appears to target patients who derive less benefit from revascularization.<sup><xref ref-type="bibr" rid="bibr8-0003319711409200">8</xref>,<xref ref-type="bibr" rid="bibr9-0003319711409200">9</xref></sup> We therefore sought to describe the prevalence and predictors of conservative medical management in patients with NSTEACS and to determine the long-term mortality associated with this strategy compared with PCI and CABG.</p>
</sec>
<sec id="section2-0003319711409200">
<title>Methods</title>
<p>The data were collected from a prospective multicenter study of the second Gulf Registry of Acute Coronary Events (Gulf RACE-2) that recruited consecutive acute coronary syndrome (ACS) patients from 6 Middle Eastern Gulf countries (Bahrain, Saudi Arabia, Qatar, Oman, United Arab Emirates [UAE], and Yemen). Patients were recruited from October 2008 until June 2009 in 65 hospitals with the diagnosis of unstable angina and non-ST-elevation myocardial infarction (NSTEMI; data merged together as NSTEACS) or ST-elevation myocardial infarction/left bundle branch block (STEMI/LBBB). An on-site cardiac catheterization laboratory was available in 43% of hospitals. The majority of hospitals (71%) had coronary care units on-site. All prospective patients with NSTEACS were enrolled, and for the purpose of this study, we excluded the following: STEMI/LBBB (n = 3613) because of some differences in revascularization therapy from patients with NSTEACS (as in primary PCI); normal coronaries or nonsignificant CAD or patent stents or grafts (n = 335); and scheduled PCI and CABG (n = 321; <xref ref-type="fig" rid="fig1-0003319711409200">Figure 1</xref>). The adjusted 30-day and 1-year mortality rates were analyzed with and without the scheduled PCI and CABG groups.</p>
<fig id="fig1-0003319711409200" position="float">
<label>Figure 1.</label>
<caption>
<p>Flow chart of the excluded groups and the stratification of the study patients into 3 comparison groups. Asterisk indicates that the adjusted 30-day and 1-year mortality rates were analyzed with and without the scheduled PCI and CABG groups. PCI indicates percutaneous coronary intervention; CABG, coronary artery bypass graft surgery</p>
</caption>
<graphic xlink:href="10.1177_0003319711409200-fig1.tif"/>
</fig>
<p>The study population was stratified into 3 groups: conservative medical management (whether the patient had undergone a diagnostic angiogram or not), PCI, and CABG. The study received ethical approval from the institutional ethical bodies in all participating countries. Full details of the methods have been published.<sup><xref ref-type="bibr" rid="bibr10-0003319711409200">10</xref>,<xref ref-type="bibr" rid="bibr11-0003319711409200">11</xref></sup> Diagnosis of NSTEACS and definitions of data variables were based on the American College of Cardiology clinical data standards.<sup><xref ref-type="bibr" rid="bibr12-0003319711409200">12</xref></sup> Central obesity was defined as a waist circumference of more than 94 cm in men and more than 80 cm in women.<sup><xref ref-type="bibr" rid="bibr13-0003319711409200">13</xref></sup> Significant CAD was determined by site investigators without the use of an angiographic core laboratory and was defined as ≥50% severity in the left main and ≥70% in other native epicardial coronary arteries (left anterior descending, circumflex, and right coronary arteries) or a major side branch of a major artery. All-cause mortality rates were captured at 30 days and 1 year by telephone contact or checking medical records for hospital visits.</p>
<sec id="section3-0003319711409200">
<title>Statistical Methods</title>
<p>Data were entered and analyzed using Statistical Package for Social Sciences version 14 (SPSS Inc., USA). Data analyses began with exploratory analyses and data checking and verifying the data quality using various techniques including range tests. We computed the prevalence of medical management as well as PCI and CABG in our patient population. Then we sought to evaluate the factors associated with the choice of medical management opposed to PCI or CABG. The range of predictors that we used included patient baseline characteristics and sociodemographic as well as clinical and medication history. We compared the categorical variables between the groups using chi-square tests, and the differences in the quantitative variables were tested using analysis of variance (ANOVA) or the Kruskal-Wallis test based on normality assumptions. Predictors associated with a patient being assigned to undergo conservative management rather than PCI or CABG were evaluated using logistic regression models. The variables for the multiple logistic regression model included the following: age, gender, nationality, country, smoking, khat chewing, body weight, diabetes, hypertension, hyperlipidemia, family history of premature coronary artery disease, history of prior myocardial infarction (MI), prior heart failure, prior CABG, prior PCI, prior peripheral arterial disease (PAD), Killip class II to IV, systolic blood pressure, ST changes on electrocardiograph (ECG), positive troponin, first creatinine; medications in the first 24 hours: aspirin, clopidogrel, β-blockers, angiotensin converting enzyme inhibitors (ACE-I)/angiotensin receptor blockers (ARB), statins; 3-vessel disease on coronary angiogram; and in-hospital adverse events (re-ischemia, re-MI, stroke, heart failure, cardiogenic shock, and major bleeding). The same model was repeated again in hospitals with catheterization laboratories only. Furthermore, we assessed whether the choice of the management decision made for each patient affected patient outcome including short- and long-term mortality. Using logistic regression models, we quantified the effect of patient management methods on patient mortality outcomes: in-hospital death, 30-day mortality, and 1-year mortality. We also evaluated mortality differences between the groups after adjusting for age, gender, Global Registry of Acute Coronary Events (GRACE) score, history of angina, prior MI, PCI, CABG, stroke, and chronic renal failure. In addition, for those scheduled for PCI and CABG who were considered to have undergone such procedures, we carried out sensitivity analyses to assess the robustness of the long-term mortality differences and whether they were affected if the scheduled patients were included or excluded. We reported the crude and adjusted ORs along with their 95% CIs and <italic>P</italic> values.</p>
</sec>
</sec>
<sec id="section4-0003319711409200">
<title>Results</title>
<sec id="section5-0003319711409200">
<title>Study Population Characteristics</title>
<p>Of 3661 patients with NSTEACS, 2859 (78.1%) had conservative medical management, 638 (17.4%) had PCI, and 164 (4.5%) had CABG (<xref ref-type="fig" rid="fig1-0003319711409200">Figure 1</xref>). Coronary angiography was performed at the index admission in 982 (26.8%) patients: 6.9% in the conservative medical management, 100% in PCI, and 89.6% in CABG groups. Compared with patients who had in-hospital revascularization (PCI or CABG), patients in the conservative medical management group were more likely to be women, be Arabian Gulf citizens, present with atypical chest pain, and have higher systolic blood pressure, diastolic blood pressure, atrial fibrillation, Killip class more than 1, history of prior CABG, congestive heart failure (CHF), stroke, PAD, chronic renal failure, khat chewing, higher serum creatinine on admission, moderate or severe left ventricular dysfunction, and a high GRACE score. However, the CABG group, compared with the other 2 groups, was more likely to have diabetes mellitus (DM), hyperlipidemia, family history of premature CAD, and/or significant left main or triple-vessel CAD on coronary angiography. The PCI group was younger than the conservative medical management and CABG groups and more likely to have a higher body mass index, prior PCI, current smoking, positive serum troponin, and single- or double-vessel CAD (<xref ref-type="table" rid="table1-0003319711409200">Table 1</xref>).</p>
<table-wrap id="table1-0003319711409200" position="float">
<label>Table 1.</label>
<caption>
<p>Patient Characteristics and In-Hospital Procedures for Conservative Medical Management, PCI, and CABG Groups</p>
</caption>
<graphic alternate-form-of="table1-0003319711409200" xlink:href="10.1177_0003319711409200-table1.tif"/>
<graphic alternate-form-of="table1-0003319711409200" xlink:href="10.1177_0003319711409200-table1a.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th align="center">Overall</th>
<th align="center">Medical management</th>
<th align="center">PCI</th>
<th align="center">CABG</th>
<th>
</th>
</tr>
<tr>
<th>Variable</th>
<th align="center">n = 3661</th>
<th align="center">n (%) = 2859 (78.1)</th>
<th align="center">n (%) = 638 (17.4)</th>
<th align="center">n (%) = 164 (4.5)</th>
<th align="center">
<italic>P</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="6">Demographics</td>
</tr>
<tr>
<td> Mean age ± SD, years</td>
<td align="center">58.9 ± 12.4</td>
<td align="center">59.5 ± 12.6</td>
<td>56.1 ± 11.5</td>
<td align="center">59.7 ± 11.2</td>
<td>&lt;.001<sup><xref ref-type="table-fn" rid="table-fn3-0003319711409200">a</xref></sup></td>
</tr>
<tr>
<td> Male, n (%)</td>
<td>2644 (72.2)</td>
<td>1996 (69.8)</td>
<td>516 (80.9)</td>
<td>132 (80.5)</td>
<td>&lt;.00<sup><xref ref-type="table-fn" rid="table-fn4-0003319711409200">b</xref></sup>
</td>
</tr>
<tr>
<td> Arabian Gulf citizen, n (%)</td>
<td>2801 (76.5)</td>
<td>2215 (77.5)</td>
<td>465 (72.9)</td>
<td>121 (73.8)</td>
<td>.033<sup><xref ref-type="table-fn" rid="table-fn4-0003319711409200">b</xref></sup>
</td>
</tr>
<tr>
<td>Body mass index (kg/m<sup>2</sup>), mean ± SD</td>
<td align="center">27.4 ± 4.6</td>
<td align="center">27.1 ± 5.9</td>
<td>28.5 ± 5.4</td>
<td align="center">27.7 ± 4.6</td>
<td>&lt;.001<sup><xref ref-type="table-fn" rid="table-fn3-0003319711409200">a</xref></sup>
</td>
</tr>
<tr>
<td> Central obesity<sup><xref ref-type="table-fn" rid="table-fn6-0003319711409200">c</xref></sup>, n (%)</td>
<td>1025 (54.9)</td>
<td>864 (54.3)</td>
<td>130 (59.9)</td>
<td>31 (51.7)</td>
<td>.260<sup><xref ref-type="table-fn" rid="table-fn4-0003319711409200">b</xref></sup>
</td>
</tr>
<tr>
<td colspan="6">Initial presentation</td>
</tr>
<tr>
<td> Typical ischemic chest pain, n (%)</td>
<td>2892 (79.0)</td>
<td>2184 (76.4)</td>
<td>558 (87.5)</td>
<td>150 (91.5)</td>
<td>&lt;.001<sup><xref ref-type="table-fn" rid="table-fn4-0003319711409200">b</xref></sup>
</td>
</tr>
<tr>
<td> Typical chest pain, n (%)</td>
<td>234 (6.4)</td>
<td>200 (7.0)</td>
<td>29 (4.5)</td>
<td>5 (3.0)</td>
<td>.015<sup><xref ref-type="table-fn" rid="table-fn4-0003319711409200">b</xref></sup>
</td>
</tr>
<tr>
<td> Cardiac arrest, n (%)</td>
<td>17 (0.5)</td>
<td>16 (0.6)</td>
<td>1 (0.2)</td>
<td>0 (0.0)</td>
<td>.453<sup><xref ref-type="table-fn" rid="table-fn4-0003319711409200">b</xref></sup>
</td>
</tr>
<tr>
<td> SBP (mm Hg), mean ± SD</td>
<td align="center">140 ± 29</td>
<td align="center">141 ± 30</td>
<td>139 ± 26</td>
<td align="center">135 ± 24</td>
<td>.045<sup><xref ref-type="table-fn" rid="table-fn3-0003319711409200">a</xref></sup>
</td>
</tr>
<tr>
<td> DBP (mm Hg), mean ± SD</td>
<td align="center">82 ± 17</td>
<td align="center">82 ± 18</td>
<td>81 ± 16</td>
<td align="center">77 ± 14</td>
<td>&lt;.001<sup><xref ref-type="table-fn" rid="table-fn3-0003319711409200">a</xref></sup>
</td>
</tr>
<tr>
<td> HR (beats/min), mean ± SD</td>
<td align="center">85 ± 21</td>
<td align="center">87 ± 22</td>
<td>80 ± 18</td>
<td align="center">80 ± 17</td>
<td>&lt;.001<sup><xref ref-type="table-fn" rid="table-fn3-0003319711409200">a</xref></sup>
</td>
</tr>
<tr>
<td> Atrial fibrillation, n (%)</td>
<td>111 (3.0)</td>
<td>103 (3.6)</td>
<td>6 (0.9)</td>
<td>2 (1.2)</td>
<td>.001<sup><xref ref-type="table-fn" rid="table-fn4-0003319711409200">b</xref></sup>
</td>
</tr>
<tr>
<td> Killip class &gt;1, n (%)</td>
<td>919 (25.1)</td>
<td>781 (27.3)</td>
<td>106 (16.6)</td>
<td>32 (19.5)</td>
<td>&lt;.001<sup><xref ref-type="table-fn" rid="table-fn4-0003319711409200">b</xref></sup>
</td>
</tr>
<tr>
<td colspan="6">History</td>
</tr>
<tr>
<td> Angina, n (%)</td>
<td>1893 (52.1)</td>
<td>1478 (52.1)</td>
<td>319 (50.2)</td>
<td>96 (58.9)</td>
<td>.137<sup><xref ref-type="table-fn" rid="table-fn4-0003319711409200">b</xref></sup>
</td>
</tr>
<tr>
<td> MI, n (%)</td>
<td>988 (27.9)</td>
<td>770 (27.8)</td>
<td>176 (28.7)</td>
<td>42 (26.8)</td>
<td>.860<sup><xref ref-type="table-fn" rid="table-fn4-0003319711409200">b</xref></sup>
</td>
</tr>
<tr>
<td> PCI, n (%)</td>
<td>454 (12.5)</td>
<td>331 (11.7)</td>
<td>109 (17.1)</td>
<td>14 (8.6)</td>
<td>&lt;.001<sup><xref ref-type="table-fn" rid="table-fn4-0003319711409200">b</xref></sup>
</td>
</tr>
<tr>
<td> CABG, n (%)</td>
<td>251 (6.9)</td>
<td>219 (7.7)</td>
<td>30 (4.7)</td>
<td>2 (1.2)</td>
<td>&lt;.001<sup><xref ref-type="table-fn" rid="table-fn4-0003319711409200">b</xref></sup>
</td>
</tr>
<tr>
<td> CHF, n (%)</td>
<td>411 (11.4)</td>
<td>382 (13.6)</td>
<td>22 (3.5)</td>
<td>7 (4.4)</td>
<td>&lt;.001<sup><xref ref-type="table-fn" rid="table-fn4-0003319711409200">b</xref></sup>
</td>
</tr>
<tr>
<td> Stroke, n (%)</td>
<td>193 (5.3)</td>
<td>174 (6.1)</td>
<td>13 (2.1)</td>
<td>6 (3.7)</td>
<td>&lt;.001<sup><xref ref-type="table-fn" rid="table-fn4-0003319711409200">b</xref></sup>
</td>
</tr>
<tr>
<td> PAD, n (%)</td>
<td>94 (2.7)</td>
<td>85 (3.1)</td>
<td>8 (1.3)</td>
<td>1 (0.6)</td>
<td>.012<sup><xref ref-type="table-fn" rid="table-fn4-0003319711409200">b</xref></sup>
</td>
</tr>
<tr>
<td> CRF, n (%)</td>
<td>253 (7.0)</td>
<td>227 (8.1)</td>
<td>22 (3.5)</td>
<td>4 (2.4)</td>
<td>&lt;.001<sup><xref ref-type="table-fn" rid="table-fn4-0003319711409200">b</xref></sup>
</td>
</tr>
<tr>
<td> Diabetes mellitus, n (%)</td>
<td>1620 (44.8)</td>
<td>1237 (43.8)</td>
<td>288 (45.6)</td>
<td>95 (58.6)</td>
<td>.001<sup><xref ref-type="table-fn" rid="table-fn4-0003319711409200">b</xref></sup>
</td>
</tr>
<tr>
<td> Hypertension, n (%)</td>
<td>2101 (57.9)</td>
<td>1645 (58.1)</td>
<td>363 (57.4)</td>
<td>93 (56.7)</td>
<td>.912<sup><xref ref-type="table-fn" rid="table-fn4-0003319711409200">b</xref></sup>
</td>
</tr>
<tr>
<td> Hyperlipidemia, n (%)</td>
<td>1534 (47.3)</td>
<td>1181 (46.1)</td>
<td>275 (50.6)</td>
<td>78 (56.1)</td>
<td>.016<sup><xref ref-type="table-fn" rid="table-fn4-0003319711409200">b</xref></sup>
</td>
</tr>
<tr>
<td> Current smoking, n (%)</td>
<td>946 (25.8)</td>
<td>666 (23.3)</td>
<td>228 (35.7)</td>
<td>52 (31.7)</td>
<td>&lt;.001<sup><xref ref-type="table-fn" rid="table-fn4-0003319711409200">b</xref></sup>
</td>
</tr>
<tr>
<td> Ex-smoker, n (%)</td>
<td>645 (17.6)</td>
<td>496 (17.3)</td>
<td>120 (18.8)</td>
<td>29 (17.7)</td>
<td>.682<sup><xref ref-type="table-fn" rid="table-fn4-0003319711409200">b</xref></sup>
</td>
</tr>
<tr>
<td> Khat chewing, n (%)</td>
<td>378 (11.2)</td>
<td>335 (12.6)</td>
<td>38 (6.7)</td>
<td>5 (3.4)</td>
<td>&lt;.001<sup><xref ref-type="table-fn" rid="table-fn4-0003319711409200">b</xref></sup>
</td>
</tr>
<tr>
<td> Family history of premature CAD, n (%)</td>
<td>380 (12.3)</td>
<td>233 (9.8)</td>
<td>117 (20.3)</td>
<td>30 (21.7)</td>
<td>&lt;.001<sup><xref ref-type="table-fn" rid="table-fn4-0003319711409200">b</xref></sup>
</td>
</tr>
<tr>
<td colspan="6">Laboratory findings</td>
</tr>
<tr>
<td> Positive serum troponin, n (%)</td>
<td>1976 (58.4)</td>
<td>1501 (56.8)</td>
<td>399 (65.6)</td>
<td>76 (56.7)</td>
<td>&lt;.001<sup><xref ref-type="table-fn" rid="table-fn4-0003319711409200">b</xref></sup>
</td>
</tr>
<tr>
<td> Peak creatinine kinase MB (ng/mL)</td>
<td align="center">40.7 ± 70.2 (n = 1999)</td>
<td align="center">41.5 ± 69.2</td>
<td align="center">40.5 ± 78.2</td>
<td align="center">28.2 ± 33.5</td>
<td>.007<sup><xref ref-type="table-fn" rid="table-fn5-0003319711409200">d</xref></sup>
</td>
</tr>
<tr>
<td> Total cholesterol (mmol/L)</td>
<td>4.8 ± 1.7 (n = 2788)</td>
<td align="center">4.9 ± 1.6</td>
<td align="center">4.5 ± 2.0</td>
<td align="center">4.4 ± 1.3</td>
<td>&lt;.001<sup><xref ref-type="table-fn" rid="table-fn3-0003319711409200">a</xref></sup>
</td>
</tr>
<tr>
<td> Triglyceride (mmol/L)</td>
<td>1.75 ± 1.11 (n = 3122)</td>
<td align="center">1.72 ± 1.10</td>
<td align="center">1.88 ± 1.12</td>
<td align="center">1.73 ± 1.07</td>
<td>.002<sup><xref ref-type="table-fn" rid="table-fn5-0003319711409200">d</xref></sup>
</td>
</tr>
<tr>
<td> High-density lipoprotein cholesterol (mmol/L)</td>
<td>1.04 ± 0.47 (n = 2624)</td>
<td align="center">1.06 ± 0.50</td>
<td align="center">0.96 ± 0.33</td>
<td align="center">0.95 ± 0.25</td>
<td>&lt;.001<sup><xref ref-type="table-fn" rid="table-fn5-0003319711409200">d</xref></sup>
</td>
</tr>
<tr>
<td> Low-density lipoprotein cholesterol (mmol/L)</td>
<td>3.07 ± 1.42 (n = 2616)</td>
<td align="center">3.12 ± 1.50</td>
<td align="center">2.88 ± 1.07</td>
<td align="center">2.91 ± 1.03</td>
<td>.001<sup><xref ref-type="table-fn" rid="table-fn5-0003319711409200">d</xref></sup>
</td>
</tr>
<tr>
<td> Fasting serum glucose (mmol/L)</td>
<td>7.26 ± 3.11 (n = 2561)</td>
<td align="center">7.24 ± 3.19</td>
<td align="center">7.28 ± 2.75</td>
<td align="center">7.54 ± 2.73</td>
<td>.044<sup><xref ref-type="table-fn" rid="table-fn5-0003319711409200">d</xref></sup>
</td>
</tr>
<tr>
<td> HbA1c (%)</td>
<td>7.54 ± 2.28 (n = 853)</td>
<td align="center">7.46 ± 2.29</td>
<td align="center">7.91 ± 2.31</td>
<td align="center">7.71 ± 1.90</td>
<td>.021<sup><xref ref-type="table-fn" rid="table-fn5-0003319711409200">d</xref></sup>
</td>
</tr>
<tr>
<td> Serum creatinine (mcmol/L)</td>
<td>106 ± 85 (n = 3627)</td>
<td align="center">108 ± 84</td>
<td align="center">98 ± 93</td>
<td align="center">93 ± 52</td>
<td>&lt;.001<sup><xref ref-type="table-fn" rid="table-fn5-0003319711409200">d</xref></sup>
</td>
</tr>
<tr>
<td> Echocardiography, n (%)</td>
<td>2625 (71.7)</td>
<td>1918 (67.1)</td>
<td>556 (87.1)</td>
<td>151 (92.1)</td>
<td>&lt;.001<sup><xref ref-type="table-fn" rid="table-fn4-0003319711409200">b</xref></sup>
</td>
</tr>
<tr>
<td> LV dysfunction, n (%)</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>&lt;.001<sup><xref ref-type="table-fn" rid="table-fn4-0003319711409200">b</xref></sup>
</td>
</tr>
<tr>
<td> Mild</td>
<td align="center">1015 (38.7)</td>
<td align="center">723 (37.7)</td>
<td align="center">227 (40.9)</td>
<td align="center">65 (43.0)</td>
<td>
</td>
</tr>
<tr>
<td> Moderate</td>
<td align="center">438 (16.7)</td>
<td align="center">349 (18.2)</td>
<td align="center">64 (11.5)</td>
<td align="center">25 (16.6)</td>
<td>
</td>
</tr>
<tr>
<td> Severe</td>
<td align="center">263 (10.0)</td>
<td align="center">233 (12.2)</td>
<td align="center">22 (4.0)</td>
<td align="center">8 (5.3)</td>
<td>
</td>
</tr>
<tr>
<td> Normal LV function</td>
<td align="center">906 (34.6)</td>
<td align="center">611 (31.9)</td>
<td align="center">242 (43.6)</td>
<td align="center">53 (35.1)</td>
<td>
</td>
</tr>
<tr>
<td colspan="6">Procedures (at index hospitalization)</td>
</tr>
<tr>
<td> Coronary angiography, n (%)</td>
<td align="center">982 (26.8)</td>
<td align="center">197 (6.9)</td>
<td align="center">638 (100)</td>
<td align="center">147 (89.6)</td>
<td>&lt;.001<sup><xref ref-type="table-fn" rid="table-fn4-0003319711409200">b</xref></sup>
</td>
</tr>
<tr>
<td> Left main, n (%)</td>
<td align="center">76 (7.8)</td>
<td align="center">16 (8.0)</td>
<td align="center">11 (1.7)</td>
<td align="center">49 (33.3)</td>
<td>&lt;.001<sup><xref ref-type="table-fn" rid="table-fn4-0003319711409200">b</xref></sup>
</td>
</tr>
<tr>
<td> 1-Vessel disease, n (%)</td>
<td align="center">345 (35.2)</td>
<td align="center">43 (21.5)</td>
<td align="center">299 (47.2)</td>
<td align="center">3 (2.0)</td>
<td>&lt;.001<sup><xref ref-type="table-fn" rid="table-fn4-0003319711409200">b</xref></sup>
</td>
</tr>
<tr>
<td> 2-Vessel disease, n (%)</td>
<td align="center">281 (28.7)</td>
<td align="center">43 (21.6)</td>
<td align="center">208 (32.9)</td>
<td align="center">30 (20.4)</td>
<td>&lt;.001<sup><xref ref-type="table-fn" rid="table-fn4-0003319711409200">b</xref></sup>
</td>
</tr>
<tr>
<td> 3-Vessel disease, n (%)</td>
<td align="center">315 (32.2)</td>
<td align="center">102 (51.3)</td>
<td align="center">103 (16.3)</td>
<td align="center">110 (74.8)</td>
<td>&lt;.001<sup><xref ref-type="table-fn" rid="table-fn4-0003319711409200">b</xref></sup>
</td>
</tr>
<tr>
<td> GRACE score</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>&lt;.001<sup><xref ref-type="table-fn" rid="table-fn4-0003319711409200">b</xref></sup>
</td>
</tr>
<tr>
<td> Low, n (%)</td>
<td align="center">1290 (35.5)</td>
<td align="center">958 (33.8)</td>
<td align="center">274 (43.2)</td>
<td align="center">58 (35.6)</td>
<td>
</td>
</tr>
<tr>
<td> Intermediate, n (%)</td>
<td align="center">1515 (41.7)</td>
<td align="center">1157 (40.8)</td>
<td align="center">287 (45.3)</td>
<td align="center">71 (43.6)</td>
<td>
</td>
</tr>
<tr>
<td> High, n (%)</td>
<td align="center">825 (22.7)</td>
<td align="center">718 (25.3)</td>
<td align="center">73 (11.5)</td>
<td align="center">34 (20.9)</td>
<td>
</td>
</tr>
<tr>
<td>Median length of stay, days (IQR)</td>
<td align="center">4 (3)</td>
<td align="center">4 (3)</td>
<td align="center">4 (3)</td>
<td align="center">16 (9)</td>
<td>&lt;.001<sup><xref ref-type="table-fn" rid="table-fn5-0003319711409200">d</xref></sup>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0003319711409200">
<p>Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; CRF, chronic renal failure; LV, left ventricular; IQR, interquartile range; GRACE, Global Registry of Acute Coronary Events; CAD, coronary artery disease; PAD, peripheral arterial disease; CHF, congestive heart failure; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft surgery; MI, myocardial infarction; MB: isoenzyme MBSD, standard deviation; HbA1c, glycosylated hemoglobin A<sub>1c</sub>; ANOVA, analysis of variance.</p>
</fn>
<fn id="table-fn2-0003319711409200">
<p><italic>P</italic> values are generated by</p></fn>
<fn id="table-fn3-0003319711409200"><p><sup>a</sup>1-way ANOVA,</p></fn>
<fn id="table-fn4-0003319711409200"><p><sup>b</sup>chi-square test, or</p></fn>
<fn id="table-fn5-0003319711409200"><p><sup>d</sup>Kruskal-Wallis test.</p></fn>
<fn id="table-fn6-0003319711409200"><p><sup>c</sup>Waist circumference &gt;94cm for men and &gt;80 cm for women.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section6-0003319711409200">
<title>Medical Therapy</title>
<p>The overall use was high for aspirin, clopidogrel, β-blockers, ACE-I/ARB, heparin (unfractionated or low-molecular-weight heparin), and statins. However, glycoprotein IIb/IIIa inhibitor (GP IIb/IIIa-I) use was low (12.6%). The highest use of in-hospital and discharge medications was in the PCI group, followed by the CABG group, except for the following: in-hospital β-blockers were highest in the CABG group; there was similar in-hospital aspirin use in all groups; and ACE-I/ARB at discharge was highest in the PCI group followed by the conservative medical management group (<xref ref-type="table" rid="table2-0003319711409200">Table 2</xref>).</p>
<table-wrap id="table2-0003319711409200" position="float">
<label>Table 2.</label>
<caption>
<p>In-Hospital Medications and at Discharge for Conservative Medical Management, PCI, and CABG Groups</p>
</caption>
<graphic alternate-form-of="table2-0003319711409200" xlink:href="10.1177_0003319711409200-table2.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th align="center">Overall</th>
<th align="center">Medical Management</th>
<th align="center">PCI</th>
<th align="center">CABG</th>
<th>
</th>
</tr>
<tr>
<th>Variable</th>
<th align="center">n = 3661</th>
<th align="center">n (%) = 2859 (78.4)</th>
<th align="center">n (%) = 638 (17.2)</th>
<th align="center">n (%) = 164 (4.4)</th>
<th align="center">
<italic>P</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="6">In-hospital medications</td>
</tr>
<tr>
<td> Aspirin</td>
<td>3592 (98.1)</td>
<td>2800 (97.9)</td>
<td>630 (98.7)</td>
<td>162 (98.8)</td>
<td>.323</td>
</tr>
<tr>
<td> Clopidogrel</td>
<td>2456 (67.4)</td>
<td>1706 (59.7)</td>
<td>617 (96.7)</td>
<td>133 (81.1)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td> β-Blocker</td>
<td>2753 (75.2)</td>
<td>2058 (72.0)</td>
<td>548 (85.9)</td>
<td>147 (89.6)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td> ACE-I and/or ARB</td>
<td>2718 (74.2)</td>
<td>2090 (73.1)</td>
<td>503 (78.8)</td>
<td>125 (76.2)</td>
<td>.009</td>
</tr>
<tr>
<td> Statins</td>
<td>3431 (93.7)</td>
<td>2657 (92.9)</td>
<td>617 (96.7)</td>
<td>157 (95.7)</td>
<td>.001</td>
</tr>
<tr>
<td> Heparin</td>
<td>2949 (80.7)</td>
<td>2222 (77.9)</td>
<td>594 (93.2)</td>
<td>133 (81.1)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td> GP IIb/IIIa inhibitors</td>
<td>457 (12.5)</td>
<td>202 (7.1)</td>
<td>240 (37.7)</td>
<td>15 (9.1)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td colspan="6">Medications at discharge</td>
</tr>
<tr>
<td> Aspirin</td>
<td>3454 (94.4)</td>
<td>2675 (93.6)</td>
<td>622 (97.6)</td>
<td>157 (95.7)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td> Clopidogrel</td>
<td>2257 (61.7)</td>
<td>1551 (54.2)</td>
<td>613 (96.2)</td>
<td>93 (56.7)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td> β-Blocker</td>
<td>2911 (79.7)</td>
<td>2196 (77.0)</td>
<td>572 (89.8)</td>
<td>143 (87.2)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td> ACE-I and/or ARB</td>
<td>2740 (75.0)</td>
<td>2119 (74.3)</td>
<td>524 (82.3)</td>
<td>97 (59.1)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td> Statins</td>
<td>3350 (91.7)</td>
<td>2578 (90.4)</td>
<td>618 (97.0)</td>
<td>154 (93.5)</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn7-0003319711409200">
<p>Abbreviations: PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft surgery; ACE-I, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; GP, glycoprotein.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section7-0003319711409200">
<title>Unadjusted In-Hospital and Long-Term Outcomes</title>
<p>In-hospital recurrent ischemia was highest in the CABG group, recurrent MI was highest in the PCI group, and CHF and cardiogenic shock were highest in the conservative medical management group. Stroke and major bleeding were similar among all groups. In-hospital mortality was highest among the CABG group (3.7%), followed by the conservative medical management group (3.3%) and the PCI group (0.9%). Thirty-day mortality was highest among the conservative medical management group (6.4%), followed by the CABG group (4.3%) and the PCI group (2.2%). One-year mortality was higher in the conservative medical management group (9.8%) than the other 2 groups (4.9% in both groups; <xref ref-type="table" rid="table3-0003319711409200">Table 3</xref>).</p>
<table-wrap id="table3-0003319711409200" position="float">
<label>Table 3.</label>
<caption>
<p>In-Hospital and Long-Term Outcomes for Conservative Medical Management, PCI, and CABG Groups</p>
</caption>
<graphic alternate-form-of="table3-0003319711409200" xlink:href="10.1177_0003319711409200-table3.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th align="center">Overall</th>
<th align="center">Medical management</th>
<th align="center">PCI</th>
<th align="center">CABG</th>
<th>
</th>
</tr>
<tr>
<th>Variable</th>
<th align="center">n = 3661</th>
<th align="center">n (%) = 2859 (78.1)</th>
<th align="center">n (%) = 638 (17.4)</th>
<th align="center">n (%) = 164 (4.5)</th>
<th align="center">
<italic>P</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="6">In-hospital outcomes</td>
</tr>
<tr>
<td> Recurrent ischemia</td>
<td>505 (13.8)</td>
<td>369 (12.9)</td>
<td>97 (15.2)</td>
<td>39 (23.8)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td> Recurrent MI</td>
<td>42 (1.1)</td>
<td>25 (0.9)</td>
<td>14 (2.2)</td>
<td>3 (1.1)</td>
<td>.013</td>
</tr>
<tr>
<td> CHF</td>
<td>488 (13.3)</td>
<td>441 (15.4)</td>
<td>40 (6.3)</td>
<td>7 (4.3)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td> Cardiogenic shock</td>
<td>138 (3.8)</td>
<td>128 (4.5)</td>
<td>7 (1.1)</td>
<td>3 (1.8)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td> Ventricular tachycardia or fibrillation</td>
<td>74 (2.0)</td>
<td>65 (2.3)</td>
<td>8 (1.3)</td>
<td>1 (0.6)</td>
<td>.107</td>
</tr>
<tr>
<td> Stroke</td>
<td>16 (0.4)</td>
<td>14 (0.5)</td>
<td>1 (0.2)</td>
<td>1 (0.6)</td>
<td>.485</td>
</tr>
<tr>
<td> Major bleeding</td>
<td>18 (0.5)</td>
<td>13 (0.4)</td>
<td>4 (0.6)</td>
<td>1 (0.6)</td>
<td>.833</td>
</tr>
<tr>
<td> Mortality</td>
<td>106 (2.9)</td>
<td>94 (3.3)</td>
<td>6 (0.9)</td>
<td>6 (3.7)</td>
<td>.005</td>
</tr>
<tr>
<td> Cardiovascular death (%)</td>
<td>90 (2.5)</td>
<td>79 (2.8)</td>
<td>6 (0.9)</td>
<td>5 (3.0)</td>
<td>.024</td>
</tr>
<tr>
<td>30-Day outcome</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>&lt;.001</td>
</tr>
<tr>
<td> Mortality</td>
<td>203 (5.5)</td>
<td>182 (6.4)</td>
<td>14 (2.2)</td>
<td>7 (4.3)</td>
<td>
</td>
</tr>
<tr>
<td> Unknown</td>
<td>357 (9.8)</td>
<td>292 (10.2)</td>
<td>55 (8.6)</td>
<td>10 (6.1)</td>
<td>
</td>
</tr>
<tr>
<td>1-Year outcome</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>&lt;.001</td>
</tr>
<tr>
<td> Mortality</td>
<td>321 (8.8)</td>
<td>284 (9.8)</td>
<td>31 (4.9)</td>
<td>8 (4.9)</td>
<td>
</td>
</tr>
<tr>
<td> Unknown</td>
<td>856 (23.4)</td>
<td>705 (24.7)</td>
<td>122 (19.1)</td>
<td>29 (17.7)</td>
<td>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn8-0003319711409200">
<p>Abbreviations: PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft surgery; MI, myocardial infarction; CHF, congestive heart failure.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section8-0003319711409200">
<title>Adjusted In-Hospital and Long-Term Mortality</title>
<p>Taking the conservative medical management group as the reference, the PCI group had significantly lower in-hospital mortality despite adjustment for age, gender, GRACE score, history of prior cardiovascular diseases, prior PCI, prior CABG, and chronic renal failure, while the CABG group had similar in-hospital mortality (<xref ref-type="table" rid="table4-0003319711409200">Table 4</xref>). The same finding of lower mortality for the PCI group persisted at the 30-day follow-up and 1-year follow-up, but the CABG group had similar mortality at 30 days and a nonsignificant trend for lower mortality at 1 year. Both the PCI and the CABG groups had lower 30-day and 1-year mortality compared with the conservative medical management group when scheduled PCI and CABG patients were assumed to have undergone the scheduled procedures after hospital discharge (data not shown).</p>
<table-wrap id="table4-0003319711409200" position="float">
<label>Table 4.</label>
<caption>
<p>Adjusted In-Hospital, 30-Day, and 1-Year Mortality Rates for the Conservative Medical Management, PCI, and CABG Groups<sup><xref ref-type="table-fn" rid="table-fn10-0003319711409200">a</xref></sup></p>
</caption>
<graphic alternate-form-of="table4-0003319711409200" xlink:href="10.1177_0003319711409200-table4.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th align="center">OR</th>
<th align="center">95% CI</th>
<th align="center">
<italic>P</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="4">In-hospital</td>
</tr>
<tr>
<td> Medical management</td>
<td>1.00</td>
<td align="center">Reference</td>
<td align="center">Reference</td>
</tr>
<tr>
<td> PCI</td>
<td>0.40</td>
<td>0.17-0.97</td>
<td>.033</td>
</tr>
<tr>
<td> CABG</td>
<td>1.39</td>
<td>0.60-3.30</td>
<td>.459</td>
</tr>
<tr>
<td colspan="4">30 Days</td>
</tr>
<tr>
<td> Medical management</td>
<td>1.00</td>
<td align="center">Reference</td>
<td align="center">Reference</td>
</tr>
<tr>
<td> PCI</td>
<td>0.44</td>
<td>0.24-0.76</td>
<td>.004</td>
</tr>
<tr>
<td> CABG</td>
<td>0.74</td>
<td>0.34-1.63</td>
<td>.458</td>
</tr>
<tr>
<td colspan="4">1 Year</td>
</tr>
<tr>
<td> Medical management</td>
<td>1.00</td>
<td align="center">Reference</td>
<td align="center">Reference</td>
</tr>
<tr>
<td> PCI</td>
<td>0.58</td>
<td>0.40-0.87</td>
<td>.008</td>
</tr>
<tr>
<td> CABG</td>
<td>0.52</td>
<td>0.25-1.10</td>
<td>.086</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn9-0003319711409200">
<p>Abbreviations: PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft surgery; MI, myocardial infarction; GRACE, Global Registry of Acute Coronary Events.</p>
</fn>
<fn id="table-fn10-0003319711409200">
<p><sup>a</sup> Adjustment for age, gender, GRACE score, history of angina, MI, PCI, CABG, stroke, and chronic renal failure.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section9-0003319711409200">
<title>Univariate and Multivariate Predictors of Conservative Medical Management</title>
<p>Univariate predictors of increased likelihood of conservative medical management were mainly age ≥80 years, female gender, country of residence (highest in Oman), Arabian Gulf citizen, khat chewing, and/or history of prior CABG, CHF, PAD, chronic renal failure, 3-vessel CAD demonstrated on angiography, and in-hospital CHF, and cardiogenic shock; predictors of less likelihood were mainly current or ex-smoking, DM, hyperlipidemia, family history of premature CAD, history of prior PCI, positive serum troponin, in-hospital clopidogrel, β-blockers, ACE-I/ARB, statins, and in-hospital recurrent ischemia or MI (<xref ref-type="table" rid="table5-0003319711409200">Tables 5</xref> and <xref ref-type="table" rid="table6-0003319711409200">6</xref>). Multivariate predictors of increased likelihood were country of residence (highest in Yemen) and history of prior CABG, while multivariate predictors of decreased likelihood were family history of premature CAD, positive serum troponin, and in-hospital clopidogrel and recurrent ischemia. When only hospitals with catheterization laboratories were included in the analysis, the multivariate predictors of increased likelihood of conservative medical management were country of residence (UAE, OR: 4.35, 95% CI: 1.49-12.65; Oman, OR: 3.02, 95% CI: 1.33-6.84), history of PAD (OR: 6.41, 95% CI: 1.89-21.72), history of CABG (OR: 2.24, 95% CI: 1.01-4.98), ACE-I/ARB in the first 24 hours of hospital admission (OR: 2.28, 95% CI: 1.19-4.35), and 3-vessel CAD on angiography (OR: 2.49, 95% CI: 1.58-3.91).</p>
<table-wrap id="table5-0003319711409200" position="float">
<label>Table 5.</label>
<caption>
<p>Univariate Predictors of Conservative Medical Management</p>
</caption>
<graphic alternate-form-of="table5-0003319711409200" xlink:href="10.1177_0003319711409200-table5.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th align="center" colspan="3">Univariate</th>
</tr>
<tr>
<th>Predictors</th>
<th align="center">OR</th>
<th align="center">95% CI</th>
<th align="center">
<italic>P</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>70-79 Years</td>
<td>1.49</td>
<td>0.98-2.28</td>
<td>.065</td>
</tr>
<tr>
<td>≥80 Years</td>
<td>2.67</td>
<td>1.51-4.70</td>
<td>.001</td>
</tr>
<tr>
<td>Female</td>
<td>1.82</td>
<td>1.50-2.21</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Arabian Gulf citizen</td>
<td>1.27</td>
<td>1.06-1.52</td>
<td>.009</td>
</tr>
<tr>
<td>Bahrain</td>
<td>1.00</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>Saudi Arabia</td>
<td>1.25</td>
<td>0.96-1.61</td>
<td>.094</td>
</tr>
<tr>
<td>UAE</td>
<td>9.76</td>
<td>6.52-14.63</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Yemen</td>
<td>10.30</td>
<td>7.08-14.98</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Oman</td>
<td>14.96</td>
<td>11.05-20.25</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Qatar</td>
<td>4.52</td>
<td>3.13-6.52</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Ex-smoker</td>
<td>0.73</td>
<td>0.59-0.91</td>
<td>.004</td>
</tr>
<tr>
<td>Current smoker</td>
<td>0.52</td>
<td>0.44-0.63</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Khat chewing</td>
<td>2.28</td>
<td>1.64-3.17</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>History of DM</td>
<td>0.84</td>
<td>0.71-0.98</td>
<td>.025</td>
</tr>
<tr>
<td>History of hyperlipidemia</td>
<td>0.80</td>
<td>0.67-0.94</td>
<td>.009</td>
</tr>
<tr>
<td>Family history of CAD</td>
<td>0.43</td>
<td>0.34-0.53</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>History of CHF</td>
<td>4.15</td>
<td>2.82-6.11</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>History of PCI</td>
<td>0.73</td>
<td>0.58-0.91</td>
<td>.005</td>
</tr>
<tr>
<td>History of CABG</td>
<td>2.00</td>
<td>1.37-2.92</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>History of PAD</td>
<td>2.66</td>
<td>1.33-5.32</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>History of CRF</td>
<td>2.70</td>
<td>1.35-5.40</td>
<td>.005</td>
</tr>
<tr>
<td>Killip class II-IV</td>
<td>1.81</td>
<td>1.48-2.21</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Systolic blood pressure</td>
<td>1.003</td>
<td>1.000-1.006</td>
<td>.032</td>
</tr>
<tr>
<td>Positive serum troponin</td>
<td>0.74</td>
<td>0.62-0.87</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Serum creatinine (Umol/L)</td>
<td>1.002</td>
<td>1.001-1.003</td>
<td>.001</td>
</tr>
<tr>
<td>In-hospital clopidogrel</td>
<td>0.10</td>
<td>0.08-0.14</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>In-hospital β-blocker</td>
<td>0.40</td>
<td>0.32-0.49</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>In-hospital ACE-I/ARB</td>
<td>0.75</td>
<td>0.62-0.91</td>
<td>.003</td>
</tr>
<tr>
<td>In-hospital statins</td>
<td>0.48</td>
<td>0.32-0.71</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>3-Vessel CAD</td>
<td>2.79</td>
<td>2.03-3.85</td>
<td>&lt;.001</td>
</tr>
<tr>
<td colspan="4">In-hospital adverse events</td>
</tr>
<tr>
<td> Recurrent ischemia</td>
<td>0.73</td>
<td>0.59-0.90</td>
<td>.003</td>
</tr>
<tr>
<td> Recurrent MI</td>
<td>0.41</td>
<td>0.22-0.76</td>
<td>.005</td>
</tr>
<tr>
<td> CHF</td>
<td>2.89</td>
<td>2.11-3.94</td>
<td>&lt;.001</td>
</tr>
<tr>
<td> Cardiogenic shock</td>
<td>2.93</td>
<td>2.15-4.00</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn11-0003319711409200">
<p>Abbreviations: OD, odds ratio; CI, confidence interval; DM, diabetes mellitus; CRF, chronic renal failure; CAD, coronary artery disease; PAD, peripheral arterial disease; CHF, congestive heart failure; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft surgery; MI, myocardial infarction; ACE-I, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table6-0003319711409200" position="float">
<label>Table 6.</label>
<caption>
<p>Multivariate Predictors of Conservative Medical Management</p>
</caption>
<graphic alternate-form-of="table6-0003319711409200" xlink:href="10.1177_0003319711409200-table6.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th align="center" colspan="3">Multivariate</th>
</tr>
<tr>
<th>Predictors</th>
<th align="center">OR ratio</th>
<th align="center">95% CI</th>
<th align="center">
<italic>P</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bahrain</td>
<td>1.00</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>Saudi Arabia</td>
<td>0.89</td>
<td>0.59-1.33</td>
<td>.564</td>
</tr>
<tr>
<td>UAE</td>
<td>9.56</td>
<td>5.25-17.43</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Yemen</td>
<td>17.52</td>
<td>7.52-40.82</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Oman</td>
<td>5.51</td>
<td>3.37-9.00</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Qatar</td>
<td>4.13</td>
<td>2.36-7.21</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Family history of CAD</td>
<td>0.52</td>
<td>0.37-0.74</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>History of CABG</td>
<td>1.97</td>
<td>1.05-3.67</td>
<td>.034</td>
</tr>
<tr>
<td>Positive serum troponin</td>
<td>0.69</td>
<td>0.52-0.90</td>
<td>.007</td>
</tr>
<tr>
<td>In-hospital clopidogrel</td>
<td>0.14</td>
<td>0.08-0.23</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Recurrent ischemia</td>
<td>0.35</td>
<td>0.25-0.51</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn12-0003319711409200">
<p>Abbreviations: OD, odds ratio; CI, confidence interval; CAD, coronary artery disease; CABG, coronary artery bypass graft surgery; UAE, United Arab Emirates.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="section10-0003319711409200">
<title>Discussion</title>
<p>Our study showed that the majority of NSTEACS patients (78.1%) in the Arabian Gulf countries did not receive revascularization with either PCI or CABG. The low overall rate of coronary angiography (26.8%) is much lower than the 60% to 82% in the CRUSADE quality improvement initiative conducted in the United States, and 30% to 50% of patients in that study underwent revascularization.<sup><xref ref-type="bibr" rid="bibr13-0003319711409200">13</xref>,<xref ref-type="bibr" rid="bibr14-0003319711409200">14</xref></sup> A similar increase in the temporal trends of coronary angiography and revascularization procedures was observed in the national registry of MI database and the GRACE registry, with an over 60% coronary angiography rate, 30% to 40% PCI rate, and 3% to 10% CABG rate.<sup><xref ref-type="bibr" rid="bibr15-0003319711409200">15</xref>,<xref ref-type="bibr" rid="bibr16-0003319711409200">16</xref></sup> However, unlike our study population, patients included in these studies were mainly high-risk NSTEMI rather than unstable angina. Fewer than half of the hospitals in our registry had an on-site catheterization facility, providing a potential explanation for this low rate: the “supply-sensitive care” phenomenon. When medical facilities are available (in this case, PCI and CABG facilities), they are used more often and vice versa.<sup><xref ref-type="bibr" rid="bibr17-0003319711409200">17</xref></sup> We have shown previously that patients with NSTEACS admitted to hospitals with an on-site catheterization facility were 16 times more likely to have an in-hospital coronary angiogram.<sup><xref ref-type="bibr" rid="bibr18-0003319711409200">18</xref></sup>
</p>
<p>In our study, medically managed patients were generally “sicker” with a more frequent history of cardiovascular diseases/risk factors and higher adverse in-hospital outcomes and long-term mortality compared with patients who had revascularization procedures. Along with the CABG group, they also had reasonable rates of in-hospital evidence-based medications, but both rates were still less than the PCI group. Plausible explanations include being older and having more comorbidities, such as chronic renal failure, than the PCI group. These factors are known to be associated with a higher risk of drug-related toxicity and complications.<sup><xref ref-type="bibr" rid="bibr19-0003319711409200">19</xref></sup> However, clopidogrel had a similar beneficial effect in medically managed patients in a subgroup analysis of the CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events) trial compared with patients treated with revascularization therapy.<sup><xref ref-type="bibr" rid="bibr20-0003319711409200">20</xref></sup> In addition, a clopidogrel-plus-aspirin combination is more effective in venous graft patency than aspirin alone at 3 months after CABG.<sup><xref ref-type="bibr" rid="bibr21-0003319711409200">21</xref></sup>
</p>
<p>The most important factor in conservative medical management was the country of residence, particularly Yemen and Oman. This finding is likely related to less availability of a wide distribution of catheterization facilities and the high prevalence of low socioeconomic strata, which have been shown to correlate with poor access to health care.<sup><xref ref-type="bibr" rid="bibr22-0003319711409200">22</xref><xref ref-type="bibr" rid="bibr23-0003319711409200"/>–<xref ref-type="bibr" rid="bibr24-0003319711409200">24</xref></sup> On the other hand, wider geographic representation of the hospitals involved in the registry might reflect a more “realistic picture” of the clinical practice in both countries than others involved in this registry. Both UAE and Qatar, despite having reasonable economic growth, also had a high use of conservative medical management, which suggests that other factors are involved in the decision-making process, such as the high rate of expatriates living in those 2 countries; this rate could potentially mean less access to revascularization therapies because of cost issues and/or patient preference to undergo invasive procedures upon returning to their home country.</p>
<p>The other predictor of conservative medical management in our study was a history of prior CABG. The SYNERGY (Superior Yield of the New Strategy of Enoxaparin, Revascularization, and Glycoprotein IIb/IIIa Inhibitors) trial included intermediate- to high-risk patients with NSTEACS and demonstrated that the strongest predictors of conservative medical management were history of prior CABG, lower body weight, lack of a recurrent MI from randomization until the time of catheterization, and 3-vessel CAD demonstrated on angiography.<sup><xref ref-type="bibr" rid="bibr25-0003319711409200">25</xref></sup> Although these factors are associated with a higher risk of ischemic events and subsequently higher absolute risk reduction with revascularization therapies, many of them are also associated with a higher risk of bleeding and/or adverse cerebrovascular ischemic events, such as transient ischemic attack and stroke.<sup><xref ref-type="bibr" rid="bibr26-0003319711409200">26</xref><xref ref-type="bibr" rid="bibr27-0003319711409200"/><xref ref-type="bibr" rid="bibr28-0003319711409200"/><xref ref-type="bibr" rid="bibr29-0003319711409200"/><xref ref-type="bibr" rid="bibr30-0003319711409200"/><xref ref-type="bibr" rid="bibr31-0003319711409200"/>–<xref ref-type="bibr" rid="bibr32-0003319711409200">32</xref></sup> In addition, revascularization might be technically challenging in patients with a history of prior CABG.<sup><xref ref-type="bibr" rid="bibr33-0003319711409200">33</xref></sup> Most of the randomized clinical trials addressing revascularization therapies have already excluded patients with these high-risk features; thus, the treating physicians opt for conservative medical management in view of an absence of strong clinical evidence of benefit. Future studies are urgently needed in such high-risk ACS subpopulations to assess the risk–benefit ratio of invasive vs conservative medical management. This “treatment-risk paradox” might arise from suboptimal risk stratification by the treating physicians, which calls for wider use of validated risk scores to potentially enhance tailoring therapies to high-risk patients.<sup><xref ref-type="bibr" rid="bibr34-0003319711409200">34</xref></sup> For example, very elderly patients deemed to be at “low risk” by physicians were typically classified as high risk by the objective and well-validated GRACE score.<sup><xref ref-type="bibr" rid="bibr35-0003319711409200">35</xref></sup> In addition, the CRUSADE bleeding score quantifies the risk of in-hospital major bleeding across all postadmission treatments and includes 8 variables: female sex, history of diabetes, prior vascular disease, heart rate, systolic blood pressure, signs of congestive heart failure, baseline hematocrit &lt;36%, and creatinine clearance.<sup><xref ref-type="bibr" rid="bibr36-0003319711409200">36</xref></sup>
</p>
<p>Our study had several limitations. As with most other registries, hospital enrollment was voluntary; thus, the study results may not be representative of clinical practice in all hospitals or a particular country in the region. However, the wide geographic distribution of several hospitals from different health care sectors in our study provides a reasonable overall representation of ACS care. We did not measure potential factors that might explain the increase in the long-term mortality rates in the conservative management group, such as nonadherence to evidence-based therapies. No data were collected regarding readmissions for MI, ischemia, or repeated revascularization, which can result in an underestimation of the long-term benefit of revascularization procedures, particularly in the CABG group. Although the PCI group had the best short- and long-term outcomes despite multiple adjustments, we may not have included all potential confounders, making it difficult to draw such definitive conclusions. However, our results are in keeping with the guideline recommendations of the benefits of an invasive strategy over conservative medical management.<sup><xref ref-type="bibr" rid="bibr1-0003319711409200">1</xref>,<xref ref-type="bibr" rid="bibr2-0003319711409200">2</xref></sup> Coronary angiogram was not done in the majority of the conservative management group, and we were thus not able to make determinations about the suitability of PCI or CABG for these patients. Nevertheless, compared with randomized controlled trials, we believe that our results more accurately reflect the “real-world” management of patients with NSTEACS.</p>
<p>In conclusion, our study showed that the majority of patients with NSTEACS in the Gulf region did not receive revascularization therapies. These patients had a higher cardiovascular baseline risk and were undertreated with evidence-based medications upon hospital discharge, and their in-hospital and long-term adverse outcomes were high. Regional variability in health care infrastructure and high-risk ACS patients were the main predictors for conservative medical management. These findings have enormous implications regarding health care policies in the region. Future studies should focus on identifying the risk-benefit ratio of an invasive strategy in high-risk ACS subpopulations, such as patients with a history of prior CABG.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>Gulf RACE-2 is a Gulf Heart Association (GHA) project and was financially supported by the GHA, <italic>Sanofi Aventis</italic>, and the College of Medicine Research Center at King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia. The sponsors had no role in study design, data collection, data analysis, writing of the report, or submission of the manuscript. The researchers obtained ethical approvals prior to the study. Special thanks to Zenaida Ramoso and Kazi Nur Asfina for data coordination and administrative assistance and also to the physicians who participated in this registry. The authors thank Dr Hajar Albinali, President of the GHA, for his leadership and support for conducting this study.</p>
</ack>
<fn-group>
<fn fn-type="other" id="fn1-0003319711409200">
<p>This study was presented at the 22nd Saudi Heart Association conference, February 2011, Riyadh, Saudi Arabia.</p>
</fn>
<fn fn-type="conflict" id="fn2-0003319711409200">
<p>The author(s) declared no conflicts of interest with respect to the authorship and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn3-0003319711409200">
<p>The author(s) received no financial support for the research and/or authorship of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0003319711409200">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anderson</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Antman</surname>
<given-names>EM</given-names>
</name>
<etal/>
</person-group>. <article-title>ACC/AHA 2007 guidelines for the management of patients with unstable angina/non–ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine</article-title>. <source>J Am Coll Cardiol</source>. <year>2007</year>;<volume>50</volume>(<issue>7</issue>):<fpage>e1</fpage>–<lpage>e157</lpage>.</citation>
</ref>
<ref id="bibr2-0003319711409200">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bassand</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Hamm</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Ardissino</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Guidelines for the diagnosis and treatment of non–ST-segment elevation acute coronary syndromes: the task force for the diagnosis and treatment of non–ST-segment elevation acute coronary syndromes of the European Society of cardiology</article-title>. <source>Eur Heart J</source>. <year>2007</year>;<volume>28</volume>(<issue>13</issue>):<fpage>1598</fpage>–<lpage>1660</lpage>.</citation>
</ref>
<ref id="bibr3-0003319711409200">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fox</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Poole-Wilson</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Henderson</surname>
<given-names>RA</given-names>
</name>
<etal/>
</person-group>. <article-title>Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial: randomized intervention trial of unstable Angina</article-title>. <source>Lancet</source>. <year>2002</year>;<volume>360</volume>(<issue>9335</issue>):<fpage>743</fpage>–<lpage>751</lpage>.</citation>
</ref>
<ref id="bibr4-0003319711409200">
<label>4</label>
<citation citation-type="journal">
<collab collab-type="author">FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators</collab>. <article-title>Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study</article-title>. <source>Lancet</source>. <year>1999</year>;<volume>354</volume>(<issue>9180</issue>):<fpage>708</fpage>–<lpage>715</lpage>.</citation>
</ref>
<ref id="bibr5-0003319711409200">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCullough</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>O’Neill</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>A prospective randomized trial of triage angiography in acute coronary syndromes ineligible for thrombolytic therapy: results of the medicine versus angiography in thrombolytic exclusion (MATE) trial</article-title>. <source>J Am Coll Cardiol</source>. <year>1998</year>;<volume>32</volume>(<issue>3</issue>):<fpage>596</fpage>–<lpage>605</lpage>.</citation>
</ref>
<ref id="bibr6-0003319711409200">
<label>6</label>
<citation citation-type="journal">
<article-title>Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non–wave myocardial infarction, results of the TIMI IIIB trial: thrombolysis in myocardial ischemia</article-title>. <source>Circulation</source>. <year>1994</year>;<volume>89</volume>(<issue>4</issue>):<fpage>1545</fpage>–<lpage>1556</lpage>.</citation>
</ref>
<ref id="bibr7-0003319711409200">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gogo</surname>
<given-names>Jr PB</given-names>
</name>
<name>
<surname>Dauerman</surname>
<given-names>HL</given-names>
</name>
<name>
<surname>Mulgund</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Changes in patterns of coronary revascularization strategies for patients with acute coronary syndromes (from the CRUSADE Quality Improvement Initiative)</article-title>. <source>Am J Cardiol</source>. <year>2007</year>;<volume>99</volume>(<issue>9</issue>):<fpage>1222</fpage>–<lpage>1226</lpage>.</citation>
</ref>
<ref id="bibr8-0003319711409200">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tricoci</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Peterson</surname>
<given-names>ED</given-names>
</name>
<name>
<surname>Mulgund</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Temporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes (results from CRUSADE)</article-title>. <source>Am J Cardiol</source>. <year>2006</year>;<volume>98</volume>(<issue>9</issue>):<fpage>1172</fpage>–<lpage>1176</lpage>.</citation>
</ref>
<ref id="bibr9-0003319711409200">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cohen</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Filby</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Roe</surname>
<given-names>MT</given-names>
</name>
<etal/>
</person-group>. <article-title>The paradoxical use of cardiac catheterization in patients with non-ST-elevation acute coronary syndromes: Lessons from the Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC /AHA Guidelines (CRUSADE) Quality Improvement Initiative</article-title>. <source>Am Heart J</source>. <year>2009</year>;<volume>158</volume>(<issue>2</issue>):<fpage>263</fpage>–<lpage>270</lpage>.</citation>
</ref>
<ref id="bibr10-0003319711409200">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zubaid</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rashed</surname>
<given-names>WA</given-names>
</name>
<name>
<surname>Al-Khaja</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Clinical presentation and outcomes of acute coronary syndromes in the Gulf Registry of Acute Coronary Events (Gulf RACE)</article-title>. <source>Saudi Med J</source>. <year>2008</year>;<volume>29</volume>(<issue>2</issue>):<fpage>251</fpage>–<lpage>255</lpage>.</citation>
</ref>
<ref id="bibr11-0003319711409200">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zubaid</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rashed</surname>
<given-names>WA</given-names>
</name>
<name>
<surname>Almahmeed</surname>
<given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>Management and outcomes of Middle Eastern patients admitted with acute coronary syndromes in the Gulf Registry of Acute Coronary Events (Gulf RACE)</article-title>. <source>Acta Cardiol</source>. <year>2009</year>;<volume>64</volume>(<issue>4</issue>):<fpage>439</fpage>–<lpage>446</lpage>.</citation>
</ref>
<ref id="bibr12-0003319711409200">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cannon</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Battler</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Brindis</surname>
<given-names>RG</given-names>
</name>
<etal/>
</person-group>. <article-title>American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee)</article-title>. <source>J Am Coll Cardiol</source>. <year>2001</year>;<volume>38</volume>(<issue>7</issue>):<fpage>2114</fpage>–<lpage>2130</lpage>.</citation>
</ref>
<ref id="bibr13-0003319711409200">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alberti</surname>
<given-names>KG</given-names>
</name>
<name>
<surname>Eckel</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Grundy</surname>
<given-names>SM</given-names>
</name>
<etal/>
</person-group>. <article-title>Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity</article-title>. <source>Circulation</source>. <year>2009</year>;<volume>120</volume>(<issue>16</issue>):<fpage>1640</fpage>–<lpage>1645</lpage>.</citation>
</ref>
<ref id="bibr14-0003319711409200">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bhatt</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Roe</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Peterson</surname>
<given-names>ED</given-names>
</name>
<etal/>
</person-group>. <article-title>Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative</article-title>. <source>JAMA</source>. <year>2004</year>;<volume>292</volume>(<issue>17</issue>):<fpage>2096</fpage>–<lpage>2104</lpage>.</citation>
</ref>
<ref id="bibr15-0003319711409200">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peterson</surname>
<given-names>ED</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Parsons</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Trends in quality of care for patients with acute myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006</article-title>. <source>Am Heart J</source>. <year>2008</year>;<volume>156</volume>(<issue>6</issue>):<fpage>1045</fpage>–<lpage>1055</lpage>.</citation>
</ref>
<ref id="bibr16-0003319711409200">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jedrzkiewiczs</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Goodman</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>RT.</given-names>
</name>
</person-group> <article-title>Temporal trends in the use of invasive cardiac procedures for non-ST-segment elevation acute coronary syndromes according to initial risk stratification</article-title>. <source>Can J Cardiol</source>. <year>2009</year>;<volume>25</volume>(<issue>11</issue>):<fpage>e370</fpage>–<lpage>e376</lpage>.</citation>
</ref>
<ref id="bibr17-0003319711409200">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gibbons</surname>
<given-names>RJ.</given-names>
</name>
</person-group> <article-title>Get with the guidelines: a new chapter?</article-title> <source>Circulation</source>. <year>2010</year>;<volume>121</volume>(<issue>2</issue>):<fpage>194</fpage>–<lpage>196</lpage>.</citation>
</ref>
<ref id="bibr18-0003319711409200">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Panduranga</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Sulaiman</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Al-Zakwani</surname>
<given-names>I</given-names>
</name>
<etal/>
</person-group>. <article-title>Utilization and determinants of in-hospital cardiac catheterization in patients with acute coronary syndrome from the Middle East</article-title>. <source>Angiology</source>. <year>2010</year>;<volume>61</volume>(<issue>8</issue>):<fpage>744</fpage>–<lpage>750</lpage>.</citation>
</ref>
<ref id="bibr19-0003319711409200">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alexander</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>AY</given-names>
</name>
<name>
<surname>Roe</surname>
<given-names>MT</given-names>
</name>
<etal/>
</person-group>. <article-title>Excess dosing of antiplatelet and antithrombin agents in the treatment of non–ST-segment elevation acute coronary syndromes</article-title>. <source>JAMA</source>. <year>2005</year>;<volume>294</volume>(<issue>24</issue>):<fpage>3108</fpage>–<lpage>3116</lpage>.</citation>
</ref>
<ref id="bibr20-0003319711409200">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fox</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Mehta</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) trial</article-title>. <source>Circulation</source>. <year>2004</year>;<volume>110</volume>(<issue>10</issue>):<fpage>1202</fpage>–<lpage>1208</lpage>.</citation>
</ref>
<ref id="bibr21-0003319711409200">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery bypass surgery: a single-center, randomized, controlled trial</article-title>. <source>J Am Coll Cardiol</source>. <year>2010</year>;<volume>56</volume>(<issue>20</issue>):<fpage>1639</fpage>–<lpage>1643</lpage>.</citation>
</ref>
<ref id="bibr22-0003319711409200">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xavier</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Pais</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Devereaux</surname>
<given-names>PJ</given-names>
</name>
<etal/>
</person-group>. <article-title>CREATE registry investigators. Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data</article-title>. <source>Lancet</source>. <year>2008</year>;<volume>371</volume>(<issue>9622</issue>):<fpage>1435</fpage>–<lpage>1442</lpage>.</citation>
</ref>
<ref id="bibr23-0003319711409200">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salomaa</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Miettinen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Niemela</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Relation of socioeconomic position to the case fatality, prognosis and treatment of myocardial infarction events; the FINMONICA MI Register Study</article-title>. <source>J Epidemiol Commun Health</source>. <year>2001</year>;<volume>55</volume>(<issue>7</issue>):<fpage>475</fpage>–<lpage>482</lpage>.</citation>
</ref>
<ref id="bibr24-0003319711409200">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alter</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Naylor</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Austin</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Tu</surname>
<given-names>JV.</given-names>
</name>
</person-group> <article-title>Effects of socioeconomic status on access to invasive cardiac procedures and on mortality after acute myocardial infarction</article-title>. <source>N Engl J Med</source>. <year>1999</year>;<volume>341</volume>(<issue>18</issue>):<fpage>1359</fpage>–<lpage>1367</lpage>.</citation>
</ref>
<ref id="bibr25-0003319711409200">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chan</surname>
<given-names>MY</given-names>
</name>
<name>
<surname>Mahaffey</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>LJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Prevalence, predictors, and impact of conservative medical management for patients with non-ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease</article-title>. <source>Am Coll Cardiol Intv</source>. <year>2008</year>;<volume>1</volume>(<issue>4</issue>):<fpage>369</fpage>–<lpage>378</lpage>.</citation>
</ref>
<ref id="bibr26-0003319711409200">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peterson</surname>
<given-names>ED</given-names>
</name>
<name>
<surname>Bynum</surname>
<given-names>DZ</given-names>
</name>
<name>
<surname>Roe</surname>
<given-names>MT.</given-names>
</name>
</person-group> <article-title>Lessons learned from the CRUSADE National Quality Improvement Initiative</article-title>. <source>Curr Cardiol Rep</source>. <year>2008</year>;<volume>10</volume>(<issue>4</issue>):<fpage>285</fpage>–<lpage>290</lpage>.</citation>
</ref>
<ref id="bibr27-0003319711409200">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alexander</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Roe</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>AY</given-names>
</name>
<etal/>
</person-group>. <article-title>Evolution in cardiovascular care for elderly patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative</article-title>. <source>J Am Coll Cardiol</source>. <year>2005</year>;<volume>46</volume>(<issue>8</issue>):<fpage>1479</fpage>–<lpage>1487</lpage>.</citation>
</ref>
<ref id="bibr28-0003319711409200">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skolnick</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Alexander</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>AY</given-names>
</name>
<etal/>
</person-group>. <article-title>Characteristics, management, and outcomes of 5,557 patients age &gt; or =90 years with acute coronary syndromes: results from the CRUSADE Initiative</article-title>. <source>J Am Coll Cardiol</source>. <year>2007</year>;<volume>49</volume>(<issue>17</issue>):<fpage>1790</fpage>–<lpage>1797</lpage>.</citation>
</ref>
<ref id="bibr29-0003319711409200">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brogan</surname>
<given-names>Jr GX</given-names>
</name>
<name>
<surname>Peterson</surname>
<given-names>ED</given-names>
</name>
<name>
<surname>Mulgund</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Treatment disparities in the care of patients with and without diabetes presenting with non–ST-segment elevation acute coronary syndromes</article-title>. <source>Diabetes Care</source>. <year>2006</year>;<volume>29</volume>(<issue>1</issue>):<fpage>9</fpage>–<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr30-0003319711409200">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roe</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>AY</given-names>
</name>
<name>
<surname>Riba</surname>
<given-names>AL</given-names>
</name>
<etal/>
</person-group>. <article-title>Impact of congestive heart failure in patients with non–ST-segment elevation acute coronary syndromes</article-title>. <source>Am J Cardiol</source>. <year>2006</year>;<volume>97</volume>(<issue>12</issue>):<fpage>1707</fpage>–<lpage>1712</lpage>.</citation>
</ref>
<ref id="bibr31-0003319711409200">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Chandra</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mulgund</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Chronic kidney disease in patients with non–ST-segment elevation acute coronary syndromes</article-title>. <source>Am J Med</source>. <year>2006</year>;<volume>119</volume>(<issue>3</issue>):<fpage>248</fpage>–<lpage>254</lpage>.</citation>
</ref>
<ref id="bibr32-0003319711409200">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Management patterns in relation to risk stratification among patients with non–ST-elevation acute coronary syndromes</article-title>. <source>Arch Intern Med</source>. <year>2007</year>;<volume>167</volume>(<issue>10</issue>):<fpage>1009</fpage>–<lpage>1016</lpage>.</citation>
</ref>
<ref id="bibr33-0003319711409200">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eagle</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Guyton</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Davidoff</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery)</article-title>. <source>J Am Coll Cardiol</source>. <year>2004</year>;<volume>44</volume>(<issue>5</issue>):<fpage>e213</fpage>–<lpage>e310</lpage>.</citation>
</ref>
<ref id="bibr34-0003319711409200">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Risk scores for risk stratification in acute coronary syndromes: useful but simpler is not necessarily better</article-title>. <source>Eur Heart J</source>. <year>2007</year>;<volume>28</volume>(<issue>9</issue>):<fpage>1072</fpage>–<lpage>1078</lpage>.</citation>
</ref>
<ref id="bibr35-0003319711409200">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bagnall</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Goodman</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>KA</given-names>
</name>
<etal/>
</person-group>. <article-title>Influence of age on use of cardiac catheterization and associated outcomes in patients with non–ST-elevation acute coronary syndromes</article-title>. <source>Am J Cardiol</source>. <year>2009</year>;<volume>103</volume>(<issue>11</issue>):<fpage>1530</fpage>–<lpage>1536</lpage>.</citation>
</ref>
<ref id="bibr36-0003319711409200">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Subherwal</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bach</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>AY</given-names>
</name>
<etal/>
</person-group>. <article-title>Baseline risk of major bleeding in non–ST-segment elevation myocardial infarction: The CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Bleeding Score</article-title>. <source>Circulation</source>. <year>2009</year>;<volume>119</volume>(<issue>14</issue>):<fpage>1873</fpage>–<lpage>1882</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>